SCHEMBL5481979

SCHEMBL5481979

COc1cc2c(cc1OC(F)F)C1CC(O)CCC1N=C2c1ccc(C(=O)N2CCN(CCN(C)C)CC2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4D Q08499 2/20 0.46
PDE4B Q07343 2/20 0.46
PDE4A P27815 1/20 0.46
PDE4C Q08493 1/20 0.46
DRD3 P35462 2/20 0.37
KMT2A Q03164 2/20 0.34
POLB P06746 2/20 0.34
PIK3CA P42336 1/20 0.34
MTOR P42345 1/20 0.34
DRD2 P14416 2/20 0.34
LMNA P02545 2/20 0.34
MEN1 O00255 1/20 0.34
MAPK7 Q13164 2/20 0.33
HTT P42858 2/20 0.33
ALDH1A1 P00352 1/20 0.33
ABCC1 P33527 1/20 0.33
KDM1A O60341 1/20 0.33
EHMT2 Q96KQ7 1/20 0.33
RCOR1 Q9UKL0 1/20 0.33
PROKR1 Q8TCW9 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5473388 0.91 PDE4D (0.45) PDE4DPDE4BPDE4APDE4CDRD3
SCHEMBL5473283 0.90 PDE4D (0.48) PDE4DPDE4BPDE4APDE4CDRD3
SCHEMBL5476150 0.88 PDE4D (0.46) PDE4DPDE4BPDE4APDE4CKMT2A
SCHEMBL5476457 0.85 PDE4D (0.42) PDE4DPDE4BPDE4APDE4CKMT2A
SCHEMBL5480188 0.85 PDE4D (0.47) PDE4DPDE4BPDE4APDE4CDRD3
SCHEMBL5481825 0.85 PDE4D (0.50) PDE4DPDE4BPDE4APDE4CDRD3
SCHEMBL5481118 0.84 PDE4D (0.42) PDE4DPDE4BPDE4APDE4CLMNA
SCHEMBL5472977 0.83 PDE4D (0.42) PDE4DPDE4BPDE4APDE4CKMT2A
SCHEMBL5480706 0.83 PDE4D (0.50) PDE4DPDE4BPDE4APDE4CALDH1A1
SCHEMBL5056505 0.82 PDE4D (0.46) PDE4DPDE4BPDE4APDE4CDRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070185149-A1 Novel amido-substituted hydroxy-6-phenylphenanthridines and their use as pde4 inhibtors ALTANA PHARMA AG (DE) 2007-08-09 US claimed
EP-1725534-A1 NOVEL AMIDO-SUBSTITUTED HYDROXY-6-PHENYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS Altana Pharma AG (DE) 2006-11-29 EP claimed
WO-2005087745-A1 NOVEL AMIDO-SUBSTITUTED HYDROXY-6-PHENYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS ALTANA PHARMA AG (DE) 2005-09-22 WO claimed
US-20070185149-A1 Novel amido-substituted hydroxy-6-phenylphenanthridines and their use as pde4 inhibtors ALTANA PHARMA AG (DE) 2007-08-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185149-A1 Novel amido-substituted hydroxy-6-phenylphenanthridines and their use as pde4 inhibtors PDE4A, PDE4B, PDE4C PDE4D 4/4885PDE4B 2/4885PDE4A 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.